GLEN ALLEN, Va.--(BUSINESS WIRE)--Osteologix, Inc. (OTCBB:OLGX) today announced that is has received a Notice of Allowance from the U.S. Patent and Trademark Office for its U.S. Patent Application Number 11/579,773 titled “High Yield and Rapid Synthesis Methods for Producing Metallo-Organic Salts” reporting allowance of claims covering certain manufacturing processes for NB S101 (strontium malonate), the Company’s lead osteoporosis drug candidate. The Company expects the patent will issue in the second half of 2009; the patent’s 20-year term would expire in 2025.
